# Sangamo Therapeutics, Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Sangamo Therapeutics, Inc). ## Overview Sangamo Therapeutics is a U.S.-based genomic medicine company focused on developing therapies and enabling technologies built around zinc finger biology, epigenetic regulation, and engineered AAV capsids. Its business combines internal research programs in neurological and genetic diseases with out-licensing and collaboration agreements with large biopharmaceutical partners. ## Products & services • Genomic medicine drug candidates for neurological and genetic diseases • Zinc finger epigenetic regulator technology • STAC-BBB capsid delivery platform • Collaboration and license agreements with biopharma partners • Research services, milestone rights, and royalty-bearing licenses - **Therapeutic programs** (20%) — Internal drug-development programs targeting serious neurological and genetic diseases. - **Capsid delivery licensing** (45%) — Licenses for the STAC-BBB capsid platform used to deliver genomic medicines to the CNS. - **Research collaborations** (25%) — Partner-funded research, development support, and related collaboration services. - **Milestones and royalties** (10%) — Upfront fees, development/commercial milestones, and potential future royalties. - Genomic medicine drug candidates for neurological and genetic diseases - Zinc finger epigenetic regulator technology - STAC-BBB capsid delivery platform - Collaboration and license agreements with biopharma partners - Research services, milestone rights, and royalty-bearing licenses ## Customers Sangamo sells primarily to large biopharmaceutical companies through collaboration and license agreements, while also advancing its own therapeutic programs toward regulatory approval and eventual commercialization. Its partner base includes companies such as Lilly, Genentech, Astellas, Pfizer, and historically Kite, reflecting a business model centered on external validation and shared development economics. The company also engages with patient communities and regulators as it develops therapies for rare and serious diseases. - **Biopharmaceutical collaborators** (primary) — Buy platform licenses, target rights, and research collaboration access to Sangamo's technologies. - **Strategic licensing partners** (primary) — License STAC-BBB and related capsid technologies for CNS delivery applications. - **Clinical development stakeholders** (secondary) — Patients, investigators, and advocacy groups that support trial enrollment and program design. - **Potential commercial partners** (emerging) — May license or co-develop late-stage assets for commercialization and market access. - Large pharma partners that license platform technology and disease targets - Biopharma collaborators funding research and development work - Potential future commercial partners for Fabry disease and CNS programs - Patients and advocacy groups that influence clinical development priorities - Regulators that determine approval pathways and label requirements ## Geography Sangamo is headquartered in the United States and conducts its research, development, and corporate activities primarily from U.S. operations. Its collaborations and licensing arrangements are global in scope, with partners that operate across the U.S., Europe, and other major pharmaceutical markets. Because the company is still development-focused, geography matters mainly through regulatory pathways, partner locations, and access to capital rather than through product sales concentration. - Headquartered in the United States - Research and corporate functions are centered in U.S. operations - Collaboration agreements are global in scope - Partner exposure includes U.S. and multinational pharma companies - Geography matters more for regulation and partnering than for sales mix ## Strategy Sangamo's strategy is to monetize its technology platforms through partnerships while advancing selected internal programs toward clinical and regulatory milestones. The company is prioritizing CNS delivery, Fabry disease readiness, and other neurology-focused opportunities where its zinc finger and capsid technologies may create differentiated value. It also seeks additional collaborations and financing to support development and preserve optionality across its pipeline. - **Fabry disease regulatory readiness** (short-term) — A late-stage submission can create a path to commercialization and partner interest. - **CNS delivery partnering** (short-term) — STAC-BBB licensing can generate upfront fees and future milestones while validating the platform. - **Pipeline and platform expansion** (medium-term) — Broader neurology programs increase the number of shots on goal and partnering opportunities. - Advance Fabry disease toward BLA submission and potential commercialization - Use STAC-BBB to expand CNS delivery opportunities with pharma partners - Secure additional collaborations to fund development and validate the platform - Prioritize neurology programs where zinc finger biology may be differentiated - Convert research assets into milestone and royalty-bearing agreements ## Risks Sangamo faces substantial financing, clinical development, and regulatory risk because it is a pre-commercial biotechnology company with long-duration R&D needs. Its revenue depends heavily on collaboration timing and partner decisions, while its ability to continue operations depends on raising additional capital. It also faces FDA approval risk, Nasdaq listing risk, and the possibility that its programs or platform technologies do not achieve expected clinical or commercial outcomes. - **Going concern and financing dependence** [critical] — The company needs substantial additional capital to fund R&D and operations. - **Collaboration revenue concentration and volatility** [high] — Revenue is driven by upfront fees, milestones, and partner reimbursements that can end or fluctuate. - **Clinical and regulatory execution** [high] — Approval depends on trial data, endpoint acceptance, and FDA review outcomes. - **Nasdaq Capital Market compliance** [high] — Delisting would reduce trading liquidity and could further constrain financing options. - **Macroeconomic and capital market conditions** [medium] — Biotech financing is sensitive to market risk appetite, rates, and sector sentiment. - Going-concern risk due to dependence on external financing - Revenue volatility from collaboration timing and partner terminations - Clinical and regulatory risk for Fabry and CNS programs - Nasdaq delisting risk could impair liquidity and capital access - FDA policy or staffing disruptions could delay approvals ## Accounting The most important accounting judgments are revenue recognition for collaboration agreements and valuation of long-lived assets. Because revenue comes from upfront fees, research reimbursements, and milestones, reported results can shift materially by quarter depending on contract timing and performance obligations. Investors should also watch impairment testing, stock-based compensation, lease accounting, and going-concern disclosures because these can materially affect reported losses and balance-sheet values. - **Revenue recognition for collaborations and licenses** — Drives quarter-to-quarter revenue swings - **Long-lived asset impairment** — Can create non-cash charges in operating expenses - **Going-concern assessment** — Material disclosure for investors and lenders - **Stock-based compensation** — Impacts reported R&D and G&A expense - Collaboration revenue recognition depends on contract timing and milestone achievement - Quarterly revenue can swing with upfront fees and partner terminations - Long-lived asset impairment reflects judgment about recoverability - Stock-based compensation is a recurring non-cash expense - Lease liabilities and going-concern disclosures affect balance-sheet analysis --- *Last updated: 2026-04-29T04:54:30.477531+00:00*